TheraSphere® vs soc Sorafenib in Hepatocellular Carcinoma with PVT

• Research type

  Research Study

• Full title

  A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (TheraSphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (Hcc) with Portal Vein Thrombosis (PVT)

• IRAS ID

  119600

• Contact name

  Tim Meyer

• Contact email

  t.meyer@ucl.ac.uk

• Sponsor organisation

  Nordion (Canada) Inc.

• Eudract number

  2012-005375-14

• Clinicaltrials.gov Identifier

  NCT01887717

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/1184

• Date of REC Opinion

  29 Aug 2013

• REC opinion

  Favourable Opinion